Prognostic indicators in WHO 2003 low-grade endometrial stromal sarcoma

被引:24
作者
Feng, Weiwei [1 ]
Hua, Keqin [1 ]
Gudlaugsson, Einar [2 ,3 ]
Yu, Yinhua [1 ,4 ]
Zhou, Xianrong [5 ]
Baak, Jan P. A. [2 ,3 ]
机构
[1] Fudan Univ, Dept Gynaecol, Obstet & Gynaecol Hosp, Shanghai 200433, Peoples R China
[2] Stavanger Univ Hosp, Dept Pathol, Stavanger, Norway
[3] Univ Bergen, Clinicla Inst 1, Bergen, Norway
[4] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA
[5] Fudan Univ, Dept Pathol, Obstet & Gynaecol Hosp, Shanghai 200433, Peoples R China
关键词
endometrial stromal sarcoma low grade; mitotic activity index; ovarian preservation; MITOTIC-ACTIVITY INDEX; BREAST-CANCER PATIENTS; UTERINE SARCOMA; OVARIAN PRESERVATION; LYMPHADENECTOMY; POPULATION; EXPERIENCE; OUTCOMES; UTERUS; REPRODUCIBILITY;
D O I
10.1111/j.1365-2559.2011.04115.x
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Aims: Endometrial stromal sarcoma (ESS) has traditionally been divided into low and high grade, but the World Health Organization (WHO, 2003) has changed the definition. Since 2003, many studies have used the old criteria, and few have focused on WHO 2003-defined ESS low grade (ESS-LG). The aim of this study was to investigate prognosticators in ESS-LG. Methods and results: We reviewed the WHO 2003 diagnostic criteria in 91 tumours (previously classified as ESS low and high grade). There were 68 cases of ESS-LG and 23 of undifferentiated endometrial sarcoma (UES). In the ESS-LG cases, the prognostic value of clinicopathological variables was studied. With a median follow-up of 79months (range: 20474 months), the recurrence and death rates were 5/68 (7%) and 1/68 (1.5%) in the ESS-LG cases. Ovarian preservation or no ovarian preservation (P<0.0001, hazard ratio (HR) 10.4) and mitotic activity index (MAI) (03 versus >3, P=0.005, HR 8.6) had independent prognostic value. Other frequently used MAI thresholds age, tumour diameter, and vessel invasion were not prognostic. Among patients without ovarian preservation (n=61), none of 53 with MAI 03 suffered recurrence, contrasting with two of eight (25%) of those with MAI >3 (P=0.003); one of these two recurrence patients died (P=0.02). Among patients with ovarian preservation (n=7), three (43%) suffered recurrence but none died, and MAI had no additional prognostic value. Conclusions: In ESS-LG, ovarian preservation and MAI >3 are associated with increased risk of recurrence.
引用
收藏
页码:675 / 687
页数:13
相关论文
共 45 条
[1]   Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients [J].
Abeler, Vera M. ;
Royne, Odd ;
Thoresen, Steinar ;
Danielsen, Havard E. ;
Nesland, Jahn M. ;
Kristensen, Gunnar B. .
HISTOPATHOLOGY, 2009, 54 (03) :355-364
[2]   Clinical study investigating the role of lymphadenectomy, surgical castration and adjuvant hormonal treatment in endometrial stromal sarcoma [J].
Amant, F. ;
De Knijf, A. ;
Van Calster, B. ;
Leunen, K. ;
Neven, P. ;
Berteloot, P. ;
Vergote, I. ;
Van Huffel, S. ;
Moerman, P. .
BRITISH JOURNAL OF CANCER, 2007, 97 (09) :1194-1199
[3]   Transition of endometrial stromal sarcoma into high-grade sarcoma [J].
Amant, Frederic ;
Woestenborghs, Heidi ;
Vandenbroucke, Vanessa ;
Berteloot, Patrick ;
Neven, Patrick ;
Moerman, Philippe ;
Vergote, Ignace .
GYNECOLOGIC ONCOLOGY, 2006, 103 (03) :1137-1140
[4]  
[Anonymous], 2009, INT J GYNECOL OBSTET, V104, P179, DOI 10.1016/j.ijgo.2008.12.009
[5]  
[Anonymous], 2003, WHO CLASSIFICATION T
[6]  
Ashraf-Ganjoei T, 2006, WORLD J SURG ONCOL, V9, P45
[7]   Proliferation is the strongest prognosticator in node-negative breast cancer: significance, error sources, alternatives and comparison with molecular prognostic markers [J].
Baak, Jan P. A. ;
Gudlaugsson, Einar ;
Skaland, Ivar ;
Guo, Lydia Hui Ru ;
Klos, Jan ;
Lende, Tone Hoel ;
Soiland, Havard ;
Janssen, Emiel A. M. ;
zur Hausen, Axel .
BREAST CANCER RESEARCH AND TREATMENT, 2009, 115 (02) :241-254
[8]   Prospective multicenter validation of the independent prognostic value of the mitotic activity index in lymph node-negative breast cancer patients younger than 55 years [J].
Baak, JPA ;
van Diest, PJ ;
Voorhorst, FJ ;
van der Wall, E ;
Beex, LVM ;
Vermorken, JB ;
Janssen, EAM .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :5993-6001
[9]   THE MULTICENTER MORPHOMETRIC MAMMARY-CARCINOMA PROJECT (MMMCP) - A NATIONWIDE PROSPECTIVE-STUDY ON REPRODUCIBILITY AND PROGNOSTIC POWER OF ROUTINE QUANTITATIVE ASSESSMENTS IN THE NETHERLANDS [J].
BAAK, JPA ;
VANDIEST, PJ ;
ARIENS, AT ;
VANBEEK, MWPM ;
BELLOT, SM ;
FIJNHEER, J ;
VANGORP, LHM ;
KWEE, WS ;
LOS, J ;
PETERSE, HC ;
RUITENBERG, HM ;
SCHAPERS, RFM ;
SCHIPPER, MEI ;
SOMSEN, JG .
PATHOLOGY RESEARCH AND PRACTICE, 1989, 185 (05) :664-670
[10]   Does Radiotherapy or Lymphadenectomy improve Survival in Endometrial Stromal Sarcoma? [J].
Barney, Brandon ;
Tward, Jonathan D. ;
Skidmore, Thomas ;
Gaffney, David K. .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2009, 19 (07) :1232-1238